A5000043369- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV-related health complications and treatments
- HIV/AIDS drug development and treatment
- HIV, Drug Use, Sexual Risk
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis B Virus Studies
- Sex work and related issues
- Hepatitis C virus research
- LGBTQ Health, Identity, and Policy
- Adolescent Sexual and Reproductive Health
- Frailty in Older Adults
- COVID-19 Clinical Research Studies
- Syphilis Diagnosis and Treatment
- Immune Cell Function and Interaction
- Reproductive tract infections research
- Neurological and metabolic disorders
- COVID-19 Impact on Reproduction
- Primary Care and Health Outcomes
- Reproductive Health and Technologies
- Nutrition and Health in Aging
- SARS-CoV-2 and COVID-19 Research
- Chronic Disease Management Strategies
- HIV/AIDS Impact and Responses
- Cardiac Imaging and Diagnostics
Royal Free London NHS Foundation Trust
2018-2025
University College London
2019-2025
The Royal Free Hospital
2019-2025
Mortimer Market Centre
2008-2024
Chelsea and Westminster Hospital NHS Foundation Trust
2011-2023
National Health Service
2008-2023
Queen Mary University of London
2023
British HIV Association
2023
St George's, University of London
2023
NHS Lothian
2023
The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA poxvirus vector NYVAC, both expressing common immunogen consisting Env, Gag, Pol, Nef polypeptide domain from human immunodeficiency virus (HIV)-1 clade C isolate, CN54. 40 volunteers were randomized to receive or nothing on day 0 at week 4, followed by NYVAC weeks 20 24. primary endpoints measured 26 28 quantification T cell responses using interferon γ enzyme-linked...
The scale of the 2022 global mpox (formerly known as monkeypox) outbreak has been unprecedented. In less than 6 months, non-endemic countries have reported more 67 000 cases a disease that had previously rare outside Africa. Mortality but hospital admission relatively common. We aimed to describe clinical and laboratory characteristics outcomes individuals admitted with associated complications, including tecovirimat recipients.
This guideline is intended for use in UK Genitourinary medicine clinics and sexual health services but likely to be of relevance all settings, including general practice Contraception Sexual Health (CASH) services, where men who have sex with (MSM) seek care or addressing the needs MSM may public benefits. For purposes this document, includes gay, bisexual other males both cis trans men. document does not provide guidance on treatment particular conditions covered British Association HIV...
The 2-drug regimen dolutegravir plus lamivudine has demonstrated long-term noninferior efficacy vs 3-/4-drug regimens (3/4DRs) in phase 3 trials. This systematic literature review summarizes clinical trial and real-world evidence evaluating impact of on inflammatory atherogenesis biomarkers people with human immunodeficiency virus type 1 (PWH).Using Ovid MEDLINE, Embase, PubMed, Cochrane library databases conference proceedings, we searched for studies published from January 2013 to 14 July...
Background: Since 2015, we prescribed dolutegravir (DTG)-based two drug regimens (DTG-2DR) for 620 people [total cohort 3133 (19.8%)]. Method: Clinic database search 1 January 15 to 31 October 21. Demographic, tolerability and HIV related data analysed. Results: In total, identified; 561 had complete data. 446 male (79.5%); median age 54 years (interquartile range 46, 59). 343 (61.1%) MSM. Nine who initiated naïvely achieved viral suppression (100%). 546/552 (99.0%) switched or continued...
Undiagnosed HIV infection is a prominent clinical issue throughout Europe that requires the continuous attention of all healthcare professionals and policymakers to prevent missed testing opportunities late diagnosis. This systematic review aimed evaluate interventions increase rates case detection in European hospitals. Out 4598 articles identified, 29 studies fulfilled selection criteria. Most were conducted single Western capital cities, only one study was from Eastern Europe. The main...
Abstract Introduction Long‐acting injectable cabotegravir + rilpivirine (CAB RPV LAI) was approved for use in virally suppressed adults the England and Wales national health service November 2021. We describe a evaluation of delivery processes outcomes 12 clinics. Methods Centres populated database using information from local policies clinical records. Services were asked to approval processes, clinic pathways, adherence guidelines. Additional data collected on reasons regimen choice,...
Abstract Background To investigate the impact of M184V/I mutation on virologic response to dolutegravir plus lamivudine (DTG + 3TC) in suppressed-switch populations, a meta-analysis was performed using outcomes from people with human immunodeficiency virus type 1 (PWH) and without before DTG 3TC switch real-world studies identified via systematic literature review. Sensitivity analyses were data PWH interventional targeted Methods Single-arm meta-analyses common- random-effects models used...
This guideline provides evidence-based guidance on the content of safer sex advice and provision brief behaviour change interventions deliverable in genitourinary (GU) medicine clinics. Much is applicable to other healthcare settings including general practice clinics providing HIV care. Advice condom use effectiveness, oral sexual practices, testing for sexually transmitted infections (STI) partner reduction provided. specific transmission infection seroadaptive behaviours negotiated safety...
Background We analysed the influence of gender on use and outcomes first-line HAART in a UK cohort. Methods Analyses included heterosexuals starting from 1998-2007 with pre-treatment CD4 + T-cell count <350 cells/mm 3 viral load (VL)>500 copies/ml. Virological suppression (<50 copies/ml), virological rebound (>500 counts at 6 12 months, clinical events treatment discontinuation/switch first year were compared using linear, logistic Cox regression. Results Compared women (...
We assessed a cohort of people living with human immunodeficiency virus (PLWH) (n = 110) and HIV negative controls 64) after 1, 2 or 3 SARS-CoV-2 vaccine doses. At all timepoints, PLWH had significantly lower neutralizing antibody (nAb) titers than HIV-negative controls. also observed delayed development neutralization in that was underpinned by reduced frequency spike-specific memory B cells (MBCs). Improved breadth seen against the Omicron variant (BA.1) third dose but nAb responses...
Objectives: To measure SARS-CoV-2 antibody seroprevalence within a cohort of adults living with HIV and correlate demographics response rates to SARS CoV-2 vaccination. Design: Initial vaccine trials for did not examine efficacy in people HIV. We undertook the SCAPE-HIV study from April 2021 November 2022 focus on this population guide future scheduling. Methods: Participants completed retrospective questionnaire. Nucleocapsid spike antibodies (anti-N anti-S) were tested. Demographic factors...
"Opt-out" Emergency Department (ED) blood-borne-virus screening enables early diagnosis, improving outcomes. Whereas some EDs encourage verbal reminders at blood draw, others emphasise "implied consent". Associations between these approaches and equity have not been explored. This retrospective cohort evaluation quantified demographic disparities in two following "reminder model" rollout. Staff attitudes were explored, identifying barriers. ED attendees from July-October 2022 identified...
Background. The optimal penetration of antiretroviral agents into the central nervous system may be a balance between providing adequate drug exposure to inhibit human immunodeficiency virus (HIV) replication while avoiding concentrations associated with neuronal toxicities. Methods. Cerebrospinal fluid (CSF) efavirenz and metabolites 7-hydroxy (7OH) 8-hydroxy (8OH) were assessed after at least 12 weeks therapy in HIV-infected subjects randomized commence regimens containing either 400 mg or...